In February 2023, Seegene met with Marta del Pino at Eurogin, the leading international conference focused on human papillomavirus (HPV) and associated cancers, to discuss the value of HPV testing and genotyping in the new cervical cancer screening paradigm.
In the wake of a transformational period for bladder cancer treatment, the time is right to harness integrated care coordination and precision medicine in order to optimize patient outcomes across the disease continuum.
The massively parallel sequencing technology based on DNA nanoballs (DNBs) — which, unlike PCR clusters, do not suffer from clonal errors — provides a high-quality, efficient, and affordable new option to North American users, said the company.
Platform- or modality-agnostic approaches to therapeutic agent design may offer more promise than platform-centric approaches. Rather than deploying a single strategy, researchers can allow the biology to dictate therapeutic design.
The noninvasive test evaluates eight 3D genomic markers and is the only test that returns a binary result to the ordering physician with high accuracy: “low probability” or “high probability” of response to an ICI.
DNAscope, a germline variant-calling pipeline from San Jose-based analytics firm Sentieon, achieved superior SNP and indel accuracy as compared to other standard datasets, according to a recent preprint from the company.
The Nu.Q NETs test is the first approved clinical assay to assess disease severity by quantifying circulating nucleosomes which make up plasma neutrophil extracellular traps, or NETs — snares of DNA expelled by neutrophils to trap and kill invading pathogens.
Seegene has joined hands with LabHouse, a testing center in Vietnam, to launch the In-Life PCR campaign for ride-hailing drivers in Ho Chi Minh and Hanoi, and the company is in talks with testing labs in countries around the world to launch the campaign in more regions,